← All trials
NCT05200364
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 22, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Jan 31, 2024
- First posted
- Jan 20, 2022
- Last posted
- Aug 2, 2022
- Enrollment
- 58
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sutro BiopharmaLead sponsor
- Sutro BiopharmaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.